ARTICLE | Company News
Tactic Pharma, Wilson Therapeutics deal
July 16, 2012 7:00 AM UTC
Wilson acquired Decuprate ( ATN-224) from Tactic. Wilson plans to develop the copper-specific binder for Wilson's disease, a rare autosomal recessive disorder caused by mutation in the ATP7B gene, which leads to an inability to properly clear excess free copper from the body. The compound has Orphan Drug designation in the U.S. for the indication. The compound completed Phase II studies in prostate cancer, melanoma and myeloma. Tactic will become a shareholder in Wilson. Details were not disclosed. ...